Androgen deficiency in the aging male: When, who, and how to investigate and treat

Urologic Clinics of North America

Volumn 29, Issue 4, 2002, Pages 975-982

  Morales, Alvaro ^a   Tenover, J Lisa ^b,c  

^a QUEEN S UNIVERSITY   (Canada)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; FLUOXYMESTERONE; METHYLTESTOSTERONE; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE;

ADULT; AGED; AGING; BLOOD SAMPLING; DRUG EFFECT; FERTILITY; HORMONAL REGULATION; HORMONE DEFICIENCY; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REVIEW; SAFETY; SEXUAL FUNCTION; SPERMATOGENESIS; SUBSTITUTION THERAPY;

AGE FACTORS; AGING; ANDROGENS; HUMANS; INFERTILITY, MALE; MALE; PATIENT SELECTION; TIME FACTORS;

EID: 0036866778     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(02)00084-8     Document Type: Review

References (40)

1. United Nations Department for Economical and Social Information and Policy Analysis. Population Division: World Population Prospects. The 1994 Revision, Document 145. New York: United Nations; 1995.
2. Wick G, Jansen-Dürr P, Berger P, et al. Diseases of aging. Vaccine 2000;18:1567-83.
3. Gooren LJG. The age-related decline of androgen levels in men: Clinically significant? Br J Urol 1996;78:763-6.
4. Morley JE. Andropause, testosterone treatment and quality of life in aging men. Cleveland Clin J Med 2000;67:880-2.
5. Neaves WB, Johnson L, Porter JC, et al. Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men. J Clin Endocrinol Metab 1984;55:756-63.
6. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone in healthy men. J Clin Endocrinol Metab 2001;86:724-31.
7. Morley JE, Kaiser FA, Perry HM, et al. Longitudinal changes in testosterone, luteinizing hormone and follicle-stimulating hormone in healthy older men. Metabolism 1997;46:410-3.
8. Tenover JL. Male senescence. In: Wang C, editor. Male Reproductive Function. Boston: Kluwer Academic Press; 1999. p. 139-56.
9. MacLeod J, Gold RZ. The male factor in fertility and infertility. Fertil Steril 1953;4:10-25.
10. Nieschlag E, Lammers U, Freischem CW, Langer K, Wickings EJ. Reproductive functions in young fathers and grandfathers. J Clin Endocrinol Metab 1982;55:676-81.
11. Heinemann LAJ, Saad F, Thiele K, Wood-Dauphinee S. The aging male's symptom rating scale: Cultural and linguistic validation into English. The Aging Male 2001;4:14-22.
12. Morley JE, Charlton E, Patrick P, et al. Validation of screening questionnaire for androgen deficiency in aging males. Metabolism 2000;49:1239-42.
13. Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol (Oxf) 2000;53:703-11.
14. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72.
15. Morales A, Heaton JPW, Johnston B, Adams M. Oral and topical treatment of erectile dysfunction: Present and future. Urol Clin N Am 1995;22:879-86.
16. Broderick GA. Editorial: Impotence. J Urol 1996;155:549.
17. Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: Results of a meta-analysis. J Urol 2000;164:371-5.
18. Bagatell CJ, Heiman JR, Rivier JE, Bremner WJ. Effects of endogenous testosterone and estradiol on behavior in normal young men. J Clin Endocrinol Metab 1994;78:711-6.
19. Buena F, Peterson MA, Swerdloff RS, et al. Sexual function does not change when serum testosterone levels are pharmacologically varied within the normal male range. Fertil Steril 1993;59:1118-23.
20. Morales A, Johnston B, Heaton JP, Lundie M. Testosterone supplementation for hypogonadal impotence: Assessment of biochemical measures and therapeutic outcomes. J Urol 1997;157:849-54.
21. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84:1966-72.
22. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999;84:2647-53.
23. Shaneyfelt T, Husein R, Bubley T, et al. Hormonal predictors of prostate cancer: A meta-analysis. J Clin Oncol 2000;18:847-53.
24. Behre HM. Testosterone therapy-effects on prostate and bone. The Aging Male 2000;3:196-202.
25. Morgenthaler A, Bruning CO, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996;276:1904-6.
26. Crook D. Androgen therapy in the aging male: Assessing the effect on heart disease. The Aging Male 1999;2:151-6.
27. Tenover JL. Experience with testosterone replacement in the elderly. Mayo Clin Proc 2000;75(Suppl):S77-S82.
28. Shahidi NT. Androgens and erythropoiesis. N Engl J Med 1971;289:72-80.
29. McCullagh EP, Jones R. Effect of androgens on the blood count of men. J Clin Endocrinol Metab 1942;2:243-7.
30. Hajjar RR, Kaiser FE, Morley FE. Outcomes of long-term testosterone replacement in older hypogonadal males: A retrospective analysis. J Clin Endocrinol Metab 1997;82:3793-6.
31. Sih R, Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: A 12-month randomized controlled trial. J Clin Endocrinol Metab 1997;82:1661-7.
32. Drinka PJ, Jochen AL, Cuisinier M, et al. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J Am Geriatr Soc 1995;43:899-901.
33. Gooren LJG. The ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994;15:212-5.
34. Cunningham GR, Cordero E, Thornby JI. Testosterone replacement with transdermal therapeutic systems: Physiological serum testosterone and elevated dihydrotestosterone levels. JAMA 1989;261:2525-30.
35. Arver S. Dobs AS, Meikle AW, et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol (Oxf) 1997;47:727-37.
36. Jordan WP, Atkinson LE. Comparison of the skin irritation potential of two testosterone transdermal systems: An investigational system and a marketed product. Clin Ther 1998;20:80-7.
37. Wang C, Berman N, Longstreth JA, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: Application of gel at one site versus four sites. A general clinical research center study. J Clin Endocrinol Metab 2000;85:964-9.
38. Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000;85:2839-53.
39. Tenover JL. Hormone replacement therapy in men. In: Healy DL, Kovacs GT, McLachlan R, Rodriquez-Armas O, editors. Reproductive Medicine in the Twenty-First Century. Boca Raton (FL): Parthenon Publishing Group; 2001. p. 383-9.
40. Morales A, Lunenfeld B. Androgen replacement therapy in aging male with secondary hypogonadism. The Aging Male 2001;4:151-62.